SCHEMBL1574553

SCHEMBL1574553

CCCN(c1ccccc1)C1CN(C(=O)Nc2cccc(SC)c2)C1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
GAA P10253 1/20 0.48
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
POLB P06746 3/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
UBE2M P61081 1/20 0.47
DCUN1D1 Q96GG9 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574905 0.92 MAPT (0.54) MAPTGAAKMT2AMEN1POLB
SCHEMBL1575336 0.87 HPGD (0.47) MAPTTP53SMN1; SMN2CYP2C9CYP2C19
SCHEMBL1574882 0.86 GRIN2B (0.53) MAPTGAAKMT2AMEN1SMN1; SMN2
SCHEMBL1574438 0.86 MAPT (0.57) MAPTGAAKMT2AMEN1POLB
SCHEMBL1574757 0.85 GRIN2B (0.54) MAPTKMT2AMEN1SMN1; SMN2UBE2M
SCHEMBL1574485 0.85 NPC1 (0.51) MAPTPOLBSMN1; SMN2UBE2MDCUN1D1
SCHEMBL1574524 0.84 MAPT (0.57) MAPTGAAKMT2AMEN1POLB
SCHEMBL1575185 0.84 S1PR2 (0.51) POLBMAPK1ALDH1A1HPGD
SCHEMBL1575548 0.84 GRIN2B (0.58) MAPTGAAKMT2AMEN1POLB
SCHEMBL1574591 0.83 RAB9A (0.48) MAPTKMT2AMEN1SMN1; SMN2UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885GAA 387/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.